Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gumusay, ÖZGE; Bayram, Ertugrul; Demirel, Burcin; Acar, Omer; Aksoy, Sercan; Baytemur, Naziyet; Sahin, Elif; Cabuk, Devrim; Basaran, GÜL; Paydas, Semra; Yaren, Arzu; Guven, Deniz; Erdogan, Atike; Demirci, Umut; Yasar, Alper; Bayoglu, İbrahim; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Davarci, Sena; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Mocan, Eda; Unal, Olcun; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, BAŞAK; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Duman, Berna; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Ozlem; Turhal, Nazim; Karadurmus, Nuri; Yalcin, Bulent; Nahit Sendur, Mehmet

doi:10.2217/fon-2022-1287

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Kahraman S., Erul E., Seyyar M., Gumusay Ö., Bayram E., Demirel B. C., ...Daha Fazla

Future oncology (London, England), 2023 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası:
Basım Tarihi: 2023
Doi Numarası: 10.2217/fon-2022-1287
Dergi Adı: Future oncology (London, England)
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.